Navigation Links
Synthetic Biologics to Report Second Quarter 2014 Financial Results
Date:8/7/2014

ROCKVILLE, Md., Aug. 7, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it intends to release its financial results for the three and six months ended June 30, 2014 on Thursday, August 14, 2014. The Company will hold an investor conference call on Thursday, August 14, at 8:30 am EDT.

During the call, Jeffrey Riley, Synthetic Biologics' Chief Executive Officer, will provide an update and review upcoming clinical milestones for the Company's anti-infective drug pipeline to address serious infections and diseases, including the prevention of C. difficile infections, reducing the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), and the treatment of Pertussis.

Mr. Riley will also provide a reminder that Rhonda Voskuhl, M.D., the lead investigator of the Phase II clinical trial evaluating Trimesta™, the Company's oral product candidate for the treatment of relapsing-remitting multiple sclerosis (MS), is scheduled to present additional clinical outcome data, including more detailed results on cognitive and disability measures. Dr. Voskuhl is scheduled to present at the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS) on September 12th in Boston. In addition, C. Evan Ballantyne, Synthetic Biologics' Chief Financial Officer, will review the Company's financial results for the three and six months ended June 30, 2014.

Interested parties should call 1-877-870-4263 (U.S. toll free), 1-855-669-9657 (Canada toll free), or +1 412-317-0790 (International), fifteen minutes before the start of the call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question & Answer Session. The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=100224. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, http://www.videonewswire.com/event.asp?id=100224, for 30 days after the call.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The Company is developing an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of Clostridium difficile (C. difficile) infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

Logo - http://photos.prnewswire.com/prnh/20130522/MM19465LOGO


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile
2. Global Synthetic Biology Market 2014-2018
3. Synthetic Biologics to Present at the 7th Annual OneMedForum San Francisco 2014 Conference
4. Green Dot Develops Compostable Synthetic Leather Made with its Terratek® Flex Bioplastic
5. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
6. Synthetic Biologics Announces Proposed Public Offering of Common Stock
7. Global Geosynthetics Market 2012-2016
8. Process holds promise for production of synthetic gasoline
9. Startup to Strengthen Synthetic Biology and Regenerative Medicine Industries with Cutting Edge Cell Products
10. Advancements in High-Speed DNA Synthesis to Drive Growth in the Global Synthetic Biology Market, According to New Report by Global Industry Analysts, Inc.
11. Synthetic Biologics SYN-004 for the Prevention of C. difficile Infections Named a "Top Project to Watch" by Elsevier Business Intelligence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... -- Cousins Properties (NYSE: CUZ ) announced today ... signed a 10-year, approximately 125,000 square-foot lease at Corporate Center, ... the Westshore submarket of Tampa, FL. ... Corporate Center for their new location in Tampa ... executive officer of Cousins Properties. "Amgen is a cutting-edge global ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), ... the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is ... ) and the US National Institutes of Health. ... ... ...
(Date:3/27/2017)... , March 27, 2017  Perthera,s Chief Bioinformatics Officer ... Subha Madhavan , Ph.D., will be speaking at ... Panels. On Monday, March 27, 2017, she will be ... More Usable for Research and Care" (from 10:30 a.m. ... 2017, she will be a participant in the "Making ...
(Date:3/27/2017)... ... ... PMG Research is pleased to announce its participation in the 2nd ... Boston on April 3-4, 2017. The CTC conference focuses on how the industry is ... closer to the patient. Clinical Trial Collaborations also will present an inaugural conference on ...
Breaking Biology Technology:
(Date:2/14/2017)... WINSTON-SALEM, N.C. , Feb. 14, 2017  Wake ... FRY-shlog), M.D., as its new chief executive officer (CEO). ... succeeds CEO John D. McConnell , M.D., who ... new position at the Medical Center, after leading it ... oversee the full scope of Wake Forest Baptist,s academic ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
Breaking Biology News(10 mins):